| abstract |
Disclosed is a pharmaceutical composition useful as an inhibitor of the progression of diseases caused by abnormal accumulation of liver fat. That is, the pharmaceutical composition of the present invention comprising a sodium / glucose cotransporter 2 inhibitor as an active ingredient has a function of suppressing abnormal fat accumulation in the liver. Inhibitors of non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hypertrophic fatty liver, diabetic fatty liver, alcoholic fatty liver or toxic fatty liver Is very suitable. |